Sichuan Hebang Biotechnology Co., Ltd. (603077.SH) Latest Company News

Oct 26, 2026, 08:24 UTC
Hesheng Biology reported first-nine-month 2026 revenue of 4.522 billion yuan, down 23.70% year over year, and net profit attributable to shareholders of 454 million yuan, up 387.48%.
Source:
- finance.sina.cn
Oct 26, 2026, 08:24 UTC
Hesheng Biology reported third-quarter 2026 revenue of 1.634 billion yuan, down 18.52% year over year, and net profit attributable to shareholders of 73.7254 million yuan, up 78.35%.
Source:
- finance.sina.cn
Sep 10, 2026, 08:23 UTC
Hebang Group, controlling shareholder of Sichuan Hebang Biotechnology, released a pledge on 218 million shares and re-pledged the same number of shares to Chongqing Rural Commercial Bank Liangjiang Branch on September 9, 2026, to fund production and operations.
Source:
- finance.sina.cn
Sep 7, 2026, 08:54 UTC
Hebang Bio's general manager Zeng Xiaoping resigned on September 4, 2026, and the company appointed Lü Wen as the new general manager on September 5, 2026.
Source:
- finance.sina.cn
Sep 4, 2026, 08:09 UTC
Hebang Group, controlling shareholder of Hebang Bio, released a pledge on 207 million shares on 2026-09-03 and re-pledged the same number of shares to Chongqing Rural Commercial Bank Liangjiang Sub-branch, with pledge term until 2029-09-02.
Source:
- finance.sina.cn
Aug 28, 2026, 09:09 UTC
Hebang Bio announced the completion of its plan to reduce its repurchased shares via centralized bidding, selling 176,630,700 shares (2% of total capital) for 479 million yuan.
Source:
- finance.sina.cn
Aug 17, 2026, 12:04 UTC
Hebang Bio announced its 2026 first-half results: net profit attributable to shareholders was 380 million yuan, up 634.30% year-on-year, with revenue of 2.888 billion yuan, down 26.34%.
Source:
- finance.sina.cn
- wap.eastmoney.com

603077.SH

Hesheng Biology reported first-nine-month 2026 revenue of 4.522 billion yuan, down 23.70% year over year, and net profit attributable to shareholders of 454 million yuan, up 387.48%.

Hesheng Biology reported third-quarter 2026 revenue of 1.634 billion yuan, down 18.52% year over year, and net profit attributable to shareholders of 73.7254 million yuan, up 78.35%.

Hebang Group, controlling shareholder of Sichuan Hebang Biotechnology, released a pledge on 218 million shares and re-pledged the same number of shares to Chongqing Rural Commercial Bank Liangjiang Branch on September 9, 2026, to fund production and operations.

Hebang Bio's general manager Zeng Xiaoping resigned on September 4, 2026, and the company appointed Lü Wen as the new general manager on September 5, 2026.

Hebang Group, controlling shareholder of Hebang Bio, released a pledge on 207 million shares on 2026-09-03 and re-pledged the same number of shares to Chongqing Rural Commercial Bank Liangjiang Sub-branch, with pledge term until 2029-09-02.

Hebang Bio announced the completion of its plan to reduce its repurchased shares via centralized bidding, selling 176,630,700 shares (2% of total capital) for 479 million yuan.

Hebang Bio announced its 2026 first-half results: net profit attributable to shareholders was 380 million yuan, up 634.30% year-on-year, with revenue of 2.888 billion yuan, down 26.34%.